	US 11,859,255 B2
	Breast cancer detection kit or device, and detection method
Satoshi Kondou, Kamakura (JP); Hitoshi Nobumasa, Kamakura (JP); Satoko Kozono, Kamakura (JP); Hiroko Sudo, Kamakura (JP); Junpei Kawauchi, Kamakura (JP); Takahiro Ochiya, Tokyo (JP); Nobuyoshi Kosaka, Tokyo (JP); Makiko Ono, Tokyo (JP); and Kenji Tamura, Tokyo (JP)
Assigned to TORAY INDUSTRIES, INC., Tokyo (JP); and NATIONAL CANCER CENTER, Tokyo (JP)
Filed by TORAY INDUSTRIES, INC., Tokyo (JP); and NATIONAL CANCER CENTER, Tokyo (JP)
Filed on Sep. 14, 2022, as Appl. No. 17/944,779.
Application 17/944,779 is a division of application No. 16/797,625, filed on Feb. 21, 2020, granted, now 11,479,822.
Application 16/797,625 is a division of application No. 15/318,328, granted, now 10,597,726, issued on Mar. 24, 2020, previously published as PCT/JP2015/066986, filed on Jun. 12, 2015.
Claims priority of application No. 2014-122672 (JP), filed on Jun. 13, 2014; and application No. 2015-069321 (JP), filed on Mar. 30, 2015.
Prior Publication US 2023/0091147 A1, Mar. 23, 2023
Int. Cl. C12Q 1/68 (2018.01); C12P 19/34 (2006.01); C12Q 1/6886 (2018.01); C12M 1/00 (2006.01); C12N 15/09 (2006.01)

CPC C12Q 1/6886 (2013.01) [C12M 1/00 (2013.01); C12Q 1/68 (2013.01); C12N 15/09 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/16 (2013.01); C12Q 2600/178 (2013.01)]

6 Claims

1. A method for detecting breast cancer in a human subject, comprising:

measuring expression level of hsa-miR-4730 in a blood, serum or plasma sample from the subject,

comparing the measured expression level of hsa-miR-4730 to a control expression level for a healthy subject;

detecting a decreased level of hsa-miR-4730 in the sample from the subject as compared to the control expression level from the sample from the healthy subject;

wherein the decreased level of hsa-miR-4730 indicates that the subject has breast cancer; and

wherein the method further comprises treating the subject for the breast cancer or performing a diagnostic procedure on the subject with the breast cancer;

wherein the treatment comprises surgery, radiotherapy, chemotherapy or a combination thereof; and

wherein the diagnostic procedure comprises mammography, ultrasonography, CT, MRI, abdominal ultrasonography, bone scintigraphy, PET, pathological examination which involves analyzing a lesion tissue under a microscope, or a combination thereof.